<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin aspart protamine and insulin aspart: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin aspart protamine and insulin aspart: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin aspart protamine and insulin aspart: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9021" href="/d/html/9021.html" rel="external">see "Insulin aspart protamine and insulin aspart: Drug information"</a> and <a class="drug drug_patient" data-topicid="11543" href="/d/html/11543.html" rel="external">see "Insulin aspart protamine and insulin aspart: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2169301"><span class="drugH1">Brand Names: US</span>
<ul>
<li>NovoLOG Mix 70/30;</li>
<li>NovoLOG Mix 70/30 FlexPen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912099"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>NovoMix 30</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2984507"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Parenteral</span>;</li>
<li>
<span class="list-set-name">Insulin, Combination</span></li></ul></div>
<div class="block dop drugH1Div" id="F46307000"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Insulin aspart protamine is an intermediate-acting insulin and insulin aspart is a rapid-acting insulin; the combination product is <b>not</b> intended for initial therapy; basal insulin requirements should be established <b>first</b> to direct dosing of combination insulin products. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1:</b> Limited data available: <b>Note:</b> Fixed ratio insulins (such as insulin aspart protamine and insulin aspart combination) are typically administered as 2 daily doses prior to meals (each dose is intended to cover 2 meals or a meal and a snack) but may be administered 3 times daily with meals if needed (Sheldon 2009). Most patients should be treated with multiple daily injections of prandial and basal insulin or continuous SUBQ insulin infusion (ADA 2023; ISPAD [Sherr 2022]; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>General insulin dosing: </i></b>The daily doses presented are expressed as the <b>total units/kg/day of all insulin formulations combined</b>. Premixed insulin is not recommended for routine use in pediatric patients; the proportion of rapid-acting to long-acting insulin is fixed; basal versus prandial dose adjustments cannot be made; premixed insulin may be useful when adherence is an issue; however, higher rates of diabetic ketoacidosis and severe hypoglycemia risk have been reported in children and adolescents receiving premixed insulins compared to basal-bolus regimens (Beck 2015; ISPAD [Cengiz 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial total daily insulin: </i>SUBQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (AACE [Blonde 2022]; ADA 2023; Peters 2013); usual range: 0.4 to 1 units/kg/day in divided doses (typically twice daily if using premixed insulin) (ADA 2023; Peters 2013; Silverstein 2005); lower doses (0.25 units/kg/day) may be used especially in young children to avoid potential hypoglycemia (Beck 2015); higher doses may be necessary for some patients (eg, concomitant steroids, puberty, sedentary lifestyle, obesity, following diabetic ketoacidosis presentation) (AACE [Blonde 2022]; Beck 2015; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Usual total daily maintenance range:</i> SUBQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Cengiz 2022]; ISPAD [Sundberg 2022]).</p>
<p style="text-indent:-2em;margin-left:10em;">Partial remission phase ("honeymoon" phase): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥7 years: 0.7 to 1 unit/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Given the fixed proportion of insulin aspart protamine and insulin aspart, independent adjustment of each component is not possible. Therefore, use of premixed insulins should be reserved for patients unwilling or unable to take more than 2 daily doses of insulin or to mix individual insulins. In these patients, consistent carbohydrate intake at each meal is essential (Peters 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570f091a-c1c1-46a6-9d95-172eadddf365">Diabetes mellitus, type 2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2:</b> Limited data available: <b>Note:</b> Premixed insulins (eg, insulin aspart protamine and insulin aspart combination) are <b>not</b> intended for initial therapy in patients with type 2 diabetes; the proportion of rapid-acting to long-acting insulin is fixed; basal versus prandial dose adjustments cannot be made; premixed insulins may be useful when adherence is an issue. Basal insulin requirements should be established <b>first</b> to direct dosing of combination insulin products. The initiation of a prandial insulin-containing product should be considered if glycemic targets are not achieved with a combination of metformin and basal insulin dose of up to 1.5 units/kg/day (AACE [Blonde 2022]; Beck 2015; ISPAD [Cengiz 2022]; ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Conversion to premixed insulins: </b></i>Children ≥10 years and Adolescents: SUBQ: Pediatric-specific data for converting patients from basal and prandial regimens to premixed insulins (such as insulin aspart protamine and insulin aspart combination) do not exist; adult data suggest decreasing insulin dose by 20% to 30% when transitioning to premixed insulins; doses are typically administered as 2 daily doses prior to meals (each dose is intended to cover 2 meals or a meal and a snack) but may be administered 3 times daily with meals if needed (ISPAD [Shah 2022]; Sheldon 2009; Wu 2015; manufacturer's labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114007"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block dohp drugH1Div" id="F51114008"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doa drugH1Div" id="F2136552"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9021" href="/d/html/9021.html" rel="external">see "Insulin aspart protamine and insulin aspart: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Insulin aspart protamine and insulin aspart combination consists of a fixed combination of intermediate-acting basal insulin (aspart protamine) and a rapid-acting prandial insulin (aspart). Risk of hypoglycemia may be higher due to less dosing flexibility compared to separate basal and prandial insulin injections (AACE/ACE [Garber 2020]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use of premixed insulin is not generally recommended in patients with type 1 diabetes. Most patients should be treated with multiple daily injections of prandial and basal insulin or continuous SUBQ insulin infusion (ADA 2023; Peters 2013). <b>The total daily doses (TDD) presented below are expressed as the total units/kg/day of all insulin formulations combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial TDD:</i></b>
<b>SUBQ:</b> ~0.4 to 0.5 units/kg/day; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (AACE/ACE [Handelsman 2015]; ADA 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Usual TDD maintenance range</i>:</b>
<b>SUBQ: </b>0.4 to 1 units/kg/day in divided doses (typically twice daily if using premixed insulin) (ADA 2023; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Dosage adjustment:</b></i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Given the fixed proportion of insulin aspart protamine and insulin aspart, independent adjustment of each component is not possible. Therefore, use of premixed insulins should be reserved for patients unwilling or unable to take more than two daily doses of insulin or to mix individual insulins. In these patients, consistent carbohydrate intake at each meal is essential (Peters 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in patients who are on stable doses of basal and prandial insulins <b>or</b> as initial insulin therapy, particularly in patients in whom a simplified insulin regimen is desirable; however, use of premixed insulin is associated with less flexibility in dosage adjustments than separate basal and prandial insulins (AACE/ACE [Garber 2020]; ADA 2023; Wexler 2022). Consider discontinuing noninsulin agents other than metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (ADA 2023; ADA/EASD [Davies 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Insulin naïve:</i>
<b> SUBQ: </b>0.2 to 0.3 units/kg/day <b>or</b> 10 to 12 units/day in 2 divided doses before meals (eg, two-thirds of the dose before breakfast and one-third of the dose before dinner) (ADA/EASD [Davies 2018]; Wexler 2022). Some experts use a minimum of 10 units/day and do not exceed 20 units/day for the initial dose (Wexler 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting from other insulin therapy:</i>
<b> SUBQ: </b>Administer the current total daily insulin dose in 2 divided doses before meals (eg, two-thirds of the dose before breakfast and one-third of the dose before dinner); may consider a 20% to 30% dose reduction when initiating premixed insulin (ADA/EASD [Davies 2018]; Wexler 2022; Wu 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage adjustment: </i>Note: </b>Individualize dosage adjustments based on patient-specific factors (eg, glucose levels, carbohydrate intake) (ADA 2023). Given the fixed proportion of basal and prandial insulin, independent adjustment of each component is not possible.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For persistently elevated glucose levels: SUBQ:</b> Consider intensification of dietary modifications and/or increasing individual premixed insulin doses by 2 to 6 units once or twice per week (depending on glucose trends) while avoiding hypoglycemia (ADA 2023; Raskin 2005; Wu 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For hypoglycemia: SUBQ: </b>For unexplained mild to moderate hypoglycemia, consider decreasing daily dose by 10% to 20% (ADA 2023); for severe hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing daily dose by 20% to 50% (AACE/ACE [Garber 2020]; Wexler 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990474"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer’s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doha drugH1Div" id="F50987744"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer’s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block adr drugH1Div" id="F2176661"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hypoglycemia (47% to 75%), severe hypoglycemia (4% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia, sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hypersensitivity at injection site (including edema, erythema, or pruritus), lipoatrophy at injection site, lipohypertrophy at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, skeletal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, pharyngitis, rhinitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Endocrine &amp; metabolic: Amyloidosis (localized cutaneous at injection site)</p></div>
<div class="block coi drugH1Div" id="F2138088"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to insulin aspart protamine, insulin aspart, or any component of the formulation; during episodes of hypoglycemia.</p></div>
<div class="block war drugH1Div" id="F2136517"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe, life-threatening hypersensitivity reactions including anaphylaxis may occur with insulin products; discontinue use if hypersensitivity occurs and treat as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of at least 75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">– ­­Weight gain: Insulin therapy is preferred over oral agents (other than metformin) if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia). A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Insulin aspart protamine and insulin aspart premixed combination products are <b>NOT</b> intended for IV or IM administration or administration in an insulin infusion pump.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not recommended for treatment of diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>
<div class="block foc drugH1Div" id="F2104231"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG® Mix 70/30: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (10 mL) </p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG® Mix 70/30 FlexPen®: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (3 mL) </p></div>
<div class="block geq drugH1Div" id="F2343844"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422165"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Insulin Aspart Prot &amp; Aspart Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(70-30) 100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (NovoLOG Mix 70/30 ReliOn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(70-30) 100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (NovoLOG Mix 70/30 Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(70-30) 100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Pen-injector</b> (NovoLOG 70/30 FlexPen ReliOn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(70-30) 100 units/mL (per mL): $11.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Pen-injector</b> (NovoLOG Mix 70/30 FlexPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(70-30) 100 units/mL (per mL): $11.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614182"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: For SUBQ administration into the thigh, upper arm, buttocks, or abdomen; <b>not for IV administration</b> or use in an insulin pump. Rotate injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis; rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Properly resuspended insulin should look uniformly white and cloudy; resuspension is easier at room temperature. Do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, if the insulin remains clear after adequate mixing, or if white particles are stuck to the bottom or wall of the container. Administer within 15 minutes before a meal (type 1 diabetes) or 15 minutes before or after a meal (type 2 diabetes). Do not mix or dilute with other insulins.</p>
<p style="text-indent:-2em;margin-left:4em;">Vials: In order to properly resuspend the insulin, gently roll vial horizontally between the palms 10 times.</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLog Mix FlexPen: In order to properly resuspend the insulin, the FlexPen should be gently rolled horizontally between the palms 10 times and inverted 180° at least 10 times. Prime the needle before each injection with 2 units of insulin; see manufacturer's labeling for specific procedure. NovoLog 70/30 FlexPen is designed to dial doses in 1-unit increments. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device. Once the insulin is injected, hold the needle in the skin for ≥6 seconds after the dose dial has returned to "0," keeping the button pressed the entire time, and then remove the needle. Do not rub the area. When there are &lt;12 units remaining in the FlexPen, replace it with a new one to ensure even mixing.</p></div>
<div class="block adm drugH1Div" id="F2136554"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Insulin aspart protamine and insulin aspart combination product is administered by SUBQ injection, typically in 2 divided doses/day with each dose intended to cover two meals or a meal and a snack; patients with type 1 diabetes should administer within 15 minutes before meal initiation; patients with type 2 diabetes may administer within 15 minutes before or after meal initiation. Administer into the thigh, upper arm, buttocks, or abdomen; absorption rates vary amongst injection sites; be consistent with area used while rotating injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">In order to properly resuspend the insulin, vials and prefilled pens should be gently rolled between the palms ten times; it is important that the vials and pens are kept horizontal throughout this process. After prefilled pens are rolled between the palms, the, prefilled pens should then be inverted until the glass ball moves from one end of the reservoir to the other ten times. Properly resuspended insulin should look uniformly white and cloudy; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, if the insulin remains clear after adequate mixing, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Do not administer</b>
<b>IM or IV, or in an insulin pump</b>. Do not dilute or mix with any other insulin formulation or solution.</p>
<p style="text-indent:-2em;margin-left:2em;">For prefilled pens, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for at least 6 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered. NovoLog 70/30 FlexPen is designed to dial doses in 1-unit increments. When there are &lt;12 units remaining in NovoLog 70/30 FlexPen, replace it with a new one to ensure even mixing.</p></div>
<div class="block sts drugH1Div" id="F2136542"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store <b>unopened </b>vials and prefilled pens under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date, or at room temperature &lt;30°C (&lt;86°F) for 14 days (prefilled pens) or 28 days (vials); do not freeze; keep away from heat and sunlight. Store <b>in-use</b> vials under refrigeration or at room temperature &lt;30°C (&lt;86°F) and use within 28 days. Store <b>in-use</b> prefilled pens at room temperature &lt;30°C (&lt;86°F) and use within 14 days; do not freeze or refrigerate.</p></div>
<div class="block usep drugH1Div" id="F53569997"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of diabetes mellitus to improve glycemic control (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F2136512"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NovoLOG Mix 70/30 may be confused with HumaLOG Mix 75/25, HumuLIN 70/30, NovoLIN 70/30, NovoLOG</p>
<p style="text-indent:2em;">NovoLOG Mix 70/30 Flexpen may be confused with NovoLOG Flexpen</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8102566"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221026"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F8102570"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block pri drugH1Div" id="F2137901"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Biphasic insulin aspart (insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]) was found to be comparable to biphasic human insulin (Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]) in initial studies of patients with gestational diabetes mellitus (Balaji 2010; Balaji 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2023).</p></div>
<div class="block mopp drugH1Div" id="F53569995"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors; some patients may be candidates for continuous glucose monitoring) (ADA 2023); electrolytes; renal function; hepatic function. Monitor weight, height (or length if &lt;24 months of age), and BMI every 3 months in pediatric patients &lt;7 years with type 1 diabetes (ISPAD [Sundberg 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">HbA<sub>1c</sub>: Monitor every 3 months; some recommendations suggest at least twice yearly may be considered in patients who have stable glycemic control and are meeting treatment goals (ADA 2023; ISPAD [de Bock 2022]; ISPAD [Shah 2022]). <b>Note:</b> In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rerp drugH1Div" id="F53569410"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Blood glucose:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 1 diabetes:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Capillary glucose measurement: 70 to 180 mg/dL (SI: 3.9 to 10 mmol/L); tighter fasting target (ie, 70 to 144 mg/dL [SI: 3.9 to 8 mmol/L]) is recommended to attain HbA<sub>1c</sub> goals (ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 2 diabetes: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting plasma glucose: 70 to 110 mg/dL (SI: 3.9 to 6.1 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial glucose: 70 to 140 mg/dL (SI: 3.9 to 7.8 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; lower targets may also be recommended when using insulin pumps and/or continuous glucose monitoring and during the "honeymoon" phase; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, have extensive comorbid conditions, or lack access to analog insulins, advanced insulin delivery technology, or continuous glucose monitoring (ADA 2023; ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients (ISPAD [Kapellen 2022]):</p>
<p style="text-indent:-2em;margin-left:6em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p></div>
<div class="block pha drugH1Div" id="F2136544"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:0em;margin-top:2em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:0em;margin-top:2em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin aspart differs from human insulin by containing aspartic acid at position B28 in comparison to the proline found in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin aspart protamine and insulin aspart combination consists of an intermediate-acting insulin (aspart protamine) and a rapid-acting insulin (aspart).</p></div>
<div class="block phk drugH1Div" id="F2136546"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SUBQ), site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>
<p style="text-indent:0em;margin-top:2em;">Onset of action: 10 to 20 minutes.</p>
<p style="text-indent:0em;margin-left:2em;">Peak effect: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: NovoLog Mix 70/30: 18 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≤9%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: NovoLog Mix 70/30: ~8 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 1.5 hours.</p></div>
<div class="block phksp drugH1Div" id="F51159880"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Insulin Cl may be reduced in patients with impaired renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038883"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Novolog mix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Novomix 30 Flexpen | Novomix 30 Penfill | Novomix 50 Flexpen | Novomix 50 Penfill | Novomix 70 Flexpen | Novomix 70 Penfill</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 201: pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.3">
<a name="ADA.3"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22468861">
<a name="22468861"></a>Balaji V, Balaji MS, Alexander C, et al. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. <i>Gynecol Endocrinol</i>. 2012;28(7):529-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/22468861/pubmed" id="22468861" target="_blank">22468861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20653150">
<a name="20653150"></a>Balaji V, Balaji MS, Alexander C, et al, "Premixed Insulin Aspart 30 (Biasp 30) Vs. Premixed Human Insulin 30 (BHI 30) in Gestational Diabetes Mellitus - A Pilot Study,"<i> J Assoc Physicians India</i>, 2010, 58:95-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/20653150/pubmed" id="20653150" target="_blank">20653150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology (AACE) clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537533">
<a name="36537533"></a>Cengiz E, Danne T, Ahmad T, et al. ISPAD clinical practice consensus guidelines 2022: insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1277-1296. doi:10.1111/pedi.13442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36537533/pubmed" id="36537533" target="_blank">36537533</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD clinical practice consensus guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi: 10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25869408">
<a name="25869408"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocr Pract</i>. 2015;21(Suppl 1):1-87. doi: 10.4158/EP15672.GL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/25869408/pubmed" id="25869408" target="_blank">25869408</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes.</i> 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; April 2021.</div>
</li>
<li>
<div class="reference">
                  NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; February 2023.</div>
</li>
<li>
<div class="reference">
                  NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; November 2019.</div>
</li>
<li>
<div class="reference">
                  NovoMix 30 (30% soluble insulin aspart and 70% insulin aspart protamine crystals) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. Alexandria, VA: American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15677776">
<a name="15677776"></a>Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. <i>Diabetes Care</i>. 2005;28(2):260-265. doi:10.2337/diacare.28.2.260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/15677776/pubmed" id="15677776" target="_blank">15677776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923163">
<a name="29923163"></a>Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <i>Clin J Gastroenterol</i>. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/29923163/pubmed" id="29923163" target="_blank">29923163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040473">
<a name="7040473"></a>Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. <i>J Clin Invest</i>. 1982;69(5):1119-1125. doi:10.1172/jci110547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/7040473/pubmed" id="7040473" target="_blank">7040473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19120431">
<a name="19120431"></a>Sheldon B, Russell-Jones, Wright J. Insulin analogues: an example of applied medical science. <i>Diabetes Obes Metab</i>. 2009;11(1)5-19. doi:10.1111/j.1463-1326.2008.01015.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/19120431/pubmed" id="19120431" target="_blank">19120431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36468192">
<a name="36468192"></a>Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. <i>Pediatr Diabetes</i>. 2022;23(8):1406-1431. doi:10.1111/pedi.13421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36468192/pubmed" id="36468192" target="_blank">36468192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al, “Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,” <i>Diabetes Care,</i> 2005, 28(1):186-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215460">
<a name="31215460"></a>Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. <i>Trials</i>. 2019;20(1):365. doi:10.1186/s13063-019-3498-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/31215460/pubmed" id="31215460" target="_blank">31215460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537520">
<a name="36537520"></a>Sundberg F, deBeaufort C, Krogvold L, et al. ISPAD clinical practice consensus guidelines 2022: managing diabetes in preschoolers. <i>Pediatr Diabetes</i>. 2022;23(8):1496-1511. doi:10.1111/pedi.13427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/36537520/pubmed" id="36537520" target="_blank">36537520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26104878">
<a name="26104878"></a>Wu T, Betty B, Downie M, et al. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. <i>Diabetes Ther</i>. 2015;6(3):273-287. doi:10.1007/s13300-015-0116-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-protamine-and-insulin-aspart-pediatric-drug-information/abstract-text/26104878/pubmed" id="26104878" target="_blank">26104878</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12539 Version 200.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
